Optimized treatment algorithm in early rheumatoid arthritis: methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid arthritis

Trial Profile

Optimized treatment algorithm in early rheumatoid arthritis: methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Adalimumab (Primary) ; Methotrexate; Triamcinolone
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms OPERA
  • Most Recent Events

    • 03 Oct 2016 Data presented at the American College of Rheumatology 2016 Annual Meeting, as per Myriad Genetics media release.
    • 11 Jun 2016 Results presented at the 17th Annual Congress of the European League Against Rheumatism
    • 10 Jun 2016 According to a Crescendo Bioscience media release, Results of changes in multi-biomarker disease activity (MBDA) score measure by VECTRA DA test, are being presented at European League Against Rheumatism (EULAR) meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top